-=Guardant Health (GH) : positive results from a study of its Guardant360 liquid biopsy

Announced positive results from the NILE study, which was a head-to-head comparison of the Guardant360 assay to standard-of-care tissue testing for the identification of guideline-recommended biomarkers in first-line advanced non-small cell lung cancer patients. Per the data, says co, Guardant360 "detected targetable genomic biomarkers at a similar rate to tissue" and thus the data "support the use of blood-based biomarker testing ahead of tissue-based testing for all newly diagnosed advanced NSCLC patients." Shares extend to new all-time highs.